Haemonetics (NYSE:HAE) was upgraded by equities research analysts at Raymond James Financial from an “underperform” rating to a “market perform” rating in a research note issued on Tuesday.
A number of other brokerages have also recently commented on HAE. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price objective for the company in a research note on Wednesday, October 25th. Morgan Stanley lifted their price objective on Haemonetics from $43.00 to $51.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Barrington Research lifted their price objective on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Finally, Craig Hallum reaffirmed a “hold” rating and set a $50.00 price objective (up from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Haemonetics currently has a consensus rating of “Hold” and an average target price of $53.33.
Shares of Haemonetics (HAE) traded down $0.24 during trading on Tuesday, hitting $58.08. The company had a trading volume of 362,200 shares, compared to its average volume of 357,887. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics has a twelve month low of $36.44 and a twelve month high of $58.99. The firm has a market capitalization of $3,070.00, a PE ratio of 829.71, a PEG ratio of 4.37 and a beta of 0.99.
In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of Haemonetics stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $54.93, for a total transaction of $257,676.63. Following the transaction, the chief accounting officer now directly owns 3,747 shares in the company, valued at $205,822.71. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pedro P. Granadillo sold 7,118 shares of Haemonetics stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $57.06, for a total value of $406,153.08. Following the transaction, the director now owns 31,663 shares in the company, valued at $1,806,690.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,368 shares of company stock worth $2,602,393. Corporate insiders own 1.20% of the company’s stock.
Several institutional investors have recently modified their holdings of HAE. Russell Investments Group Ltd. lifted its holdings in shares of Haemonetics by 12.2% in the second quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock valued at $928,000 after purchasing an additional 2,553 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Haemonetics by 4.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 568,454 shares of the medical instruments supplier’s stock valued at $22,449,000 after purchasing an additional 24,451 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Haemonetics by 9.4% in the second quarter. Legal & General Group Plc now owns 99,893 shares of the medical instruments supplier’s stock valued at $3,943,000 after purchasing an additional 8,543 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of Haemonetics by 63.8% in the second quarter. BNP Paribas Arbitrage SA now owns 17,996 shares of the medical instruments supplier’s stock valued at $711,000 after purchasing an additional 7,009 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Haemonetics by 0.9% in the second quarter. American Century Companies Inc. now owns 46,271 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 425 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Market News and is the sole property of of American Market News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/02/haemonetics-hae-upgraded-at-raymond-james-financial.html.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
